Oncotarget

Reviews:

DARPP-32: from neurotransmission to cancer

Abbes Belkhiri _, Shoumin Zhu and Wael El-Rifai

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:17631-17640. https://doi.org/10.18632/oncotarget.7268

Metrics: PDF 1418 views  |   HTML 1873 views  |   ?  


Abstract

Abbes Belkhiri1, Shoumin Zhu1 and Wael El-Rifai1,2

1 Department of Surgery, Cancer Biology, and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA

2 Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA

Correspondence to:

Wael El-Rifai, email:

Keywords: DARPP-32, t-DARPP, PPP1R1B, neurotransmission, cancer

Received: November 05, 2015 Accepted: January 29, 2016 Published: February 08, 2016

Abstract

Dopamine and cAMP-regulated phosphoprotein Mr 32,000 (DARPP-32), also known as phosphoprotein phosphatase-1 regulatory subunit 1B (PPP1R1B), was initially discovered as a substrate of dopamine-activated protein kinase A (PKA) in the neostriatum in the brain. While phosphorylation at Thr-34 by PKA converts DARPP-32 into a potent inhibitor of protein phosphatase 1 (PP1), phosphorylation at Thr-75 transforms DARPP-32 into an inhibitor of PKA. Through regulation of DARPP-32 phosphorylation and modulation of protein phosphatase and kinase activities, DARPP-32 plays a critical role in mediating the biochemical, electrophysiological, and behavioral effects controlled by dopamine and other neurotransmitters in response to drugs of abuse and psychostimulants. Altered expression of DARPP-32 and its truncated isoform (t-DARPP), specifically in the prefrontal cortex, has been associated with schizophrenia and bipolar disorder. Moreover, cleavage of DARPP-32 by calpain has been implicated in Alzheimer’s disease. Amplification of the genomic locus of DARPP-32 at 17q12 has been described in several cancers. DARPP-32 and t-DARPP are frequently overexpressed at the mRNA and protein levels in adenocarcinomas of the breast, prostate, colon, and stomach. Several studies demonstrated the pro-survival, pro-invasion, and pro-angiogenic functions of DARPP-32 in cancer. Overexpression of DARPP-32 and t-DARPP also promotes chemotherapeutic drug resistance and cell proliferation in gastric and breast cancers through regulation of pro-oncogenic signal transduction pathways. The expansion of DARPP-32 research from neurotransmission to cancer underscores the broad scope and implication of this protein in disparate human diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7268